+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Myelogenous Leukemia Therapeutics Market by Therapy Type, Treatment Line, Mechanism of Action, Route of Administration, End User, Distribution Channel, Dosage Form, Patient Age Group - Global Forecast to 2030- Product Image
Chronic Myelogenous Leukemia Therapeutics Market by Therapy Type, Treatment Line, Mechanism of Action, Route of Administration, End User, Distribution Channel, Dosage Form, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Chronic Myelogenous Leukemia Therapeutics Market by Therapy Type, Treatment Line, Mechanism of Action, Route of Administration, End User, Distribution Channel, Dosage Form, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010863
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Myelogenous Leukemia Therapeutics Market grew from USD 8.27 billion in 2024 to USD 8.94 billion in 2025. It is expected to continue growing at a CAGR of 7.78%, reaching USD 12.97 billion by 2030.

Navigating the Evolution of CML Therapeutics

Chronic myelogenous leukemia (CML) has evolved from a uniformly fatal disease to a manageable chronic condition thanks to decades of scientific breakthroughs and pharmaceutical innovation. Advances in molecular diagnostics, coupled with the advent of tyrosine kinase inhibitors (TKIs), have dramatically improved survival rates and quality of life for patients. Yet, as the therapeutic landscape expands, decision-makers face an increasingly complex array of treatment options, regulatory challenges, and market dynamics.

This executive summary distills the key insights shaping the current and future trajectory of the CML therapeutics market. Drawing on rigorous research and expert perspectives, the report illuminates emerging treatment modalities, commercial pressures, segmentation drivers, regional variances, and the strategic moves of leading biopharma players. Readers will gain a holistic understanding of the forces redefining CML care pathways and actionable recommendations to navigate growth opportunities within this competitive environment.

Emerging Breakthroughs Redefining CML Management

Over the past decade, the CML arena has witnessed transformative shifts that are redefining clinical practice and market structures alike. The maturation of first-generation TKIs into standard first-line therapies has paved the way for next-generation inhibitors with improved potency and safety profiles. Concurrently, combination regimens that pair TKIs with immunomodulatory agents or monoclonal antibodies are gaining traction, offering the prospect of deeper molecular responses and sustained treatment-free remission.

Beyond pharmacology, digital health platforms are enhancing patient monitoring and adherence, enabling real-time dose adjustments and richer data capture. Advances in genomic profiling and biomarker discovery are ushering in a precision medicine era, where treatment selection is increasingly tailored to individual mutation status and resistance patterns. Meanwhile, the entry of generic TKIs is intensifying price competition, forcing patent-holder companies to adopt innovative patient support programs and value-based contracting models. Collectively, these developments are rebalancing the competitive landscape, challenging incumbents and newcomers to differentiate through clinical advantage, cost-effectiveness, and patient engagement.

Assessing the 2025 US Tariffs Impact on CML Treatments

In 2025, the imposition of incremental tariffs on pharmaceutical imports in the United States introduced new headwinds for CML drug manufacturers and distributors. These levies have raised the landed cost of active pharmaceutical ingredients and finished therapies, exerting price pressure on both branded and generic products. Manufacturers have responded by optimizing supply chains, onshoring critical API production, and renegotiating contracts with contract manufacturing organizations to mitigate tariff-driven cost inflation.

Simultaneously, some payers have intensified scrutiny of reimbursement levels, driving outcomes-based pricing agreements that tie revenues to patient milestones such as major molecular response. Market access teams are recalibrating launch sequences and commercial plans to accommodate extended approval timelines and potential import delays. Despite these challenges, the robust clinical value proposition of advanced TKIs and emerging combination protocols sustains strong demand, underscoring the resilience and adaptability of stakeholders across the CML ecosystem.

In-Depth Segmentation Unveils Market Nuances

An in-depth segmentation analysis reveals nuanced growth drivers across therapy type, treatment line, mechanism of action, administration route, end user, distribution channel, dosage form, and patient age group. The therapy type dimension distinguishes chemotherapy agents-such as busulfan, hydroxyurea, and interferon alfa-from combination protocols that integrate TKIs with chemotherapy or monoclonal antibodies, while spotlighting the generational evolution of TKIs from first-generation imatinib through second-generation bosutinib, dasatinib and nilotinib to third-generation ponatinib.

Treatment line segmentation differentiates first-line initiation strategies from second-line switches and third-line or beyond salvage interventions, reflecting rising rates of resistance and intolerance. The mechanism-of-action perspective parallels therapy type but underscores the scientific rationale for targeting BCR-ABL kinase activity alone or in concert with complementary pathways. Route of administration contrasts convenient oral dosing with parenteral regimens delivered intravenously or subcutaneously, each bearing distinct compliance and infrastructure requirements. End users range from outpatient clinics and home care settings to hospitals and specialized oncology centers, illustrating diverse care delivery models. Distribution channels encompass hospital, online, and retail pharmacies, each presenting unique reimbursement and logistics profiles. Dosage form segmentation spans capsules, tablets, injectable solutions and powders, while patient age groups segment adult, geriatric and pediatric cohorts, each with tailored safety and efficacy considerations. This multidimensional view equips stakeholders with a comprehensive map of unmet needs and high-growth pockets in the CML market.

Regional Dynamics Shaping CML Therapeutic Uptake

Regional insights underscore the heterogeneous nature of CML adoption and growth across the Americas, Europe, Middle East & Africa and Asia-Pacific. In North America, favorable reimbursement policies and widespread TKI familiarity continue to sustain high per-patient expenditure, while patient assistance programs cushion cost barriers. LatAm markets exhibit variable access influenced by public funding constraints, though increasing regulatory harmonization and private insurance uptake are expanding treatment penetration.

Across Europe, Middle East & Africa, the legacy of centralized approval processes through agencies such as EMA contrasts with localized procurement models in the Gulf Cooperation Council and North African markets. Price referencing and tender systems drive aggressive cost containment, prompting multinational companies to deploy tiered pricing and differential patient support. In Asia-Pacific, rising incidence rates, growing healthcare budgets and expanding oncology infrastructures in countries like China, India and South Korea are fueling demand, yet generics erosion and government-led price caps temper revenue growth. Understanding these geographic dynamics is imperative for crafting targeted market entry strategies and optimizing resource allocation.

Strategic Postures of Leading Biopharma Players

Leading biopharma companies are deploying distinct strategies to defend and advance their positions in the CML space. Established players with broad TKI portfolios are investing in lifecycle management for mature assets, pursuing label expansions, novel dosing regimens and real-world evidence generation. Concurrently, innovators are forging collaborations around biomarker-driven combination studies, leveraging proprietary immunotherapy platforms to complement kinase inhibition.

Strategic partnerships and licensing deals are accelerating access to cutting-edge molecules and expanding geographic footprints. Meanwhile, targeted acquisitions of specialty oncology firms and CDMO capabilities are bolstering manufacturing agility and pipeline depth. Several companies are also piloting value-based contracting frameworks with payers to align reimbursement with long-term patient outcomes, fostering risk-sharing and reinforcing clinical credibility. Collectively, these initiatives reflect a market in which competitive advantage is increasingly derived from scientific differentiation, operational excellence and adaptive commercialization models.

Actionable Strategies to Navigate the CML Market

Industry leaders should prioritize investment in next-generation TKIs and rationally designed combination regimens that address resistant CML clones and deepen molecular remission. Strengthening local manufacturing or forging regional API partnerships can alleviate tariff pressures and ensure uninterrupted supply chains. In parallel, forging alliances with diagnostic firms to integrate genomic profiling at diagnosis and progression can establish data-driven treatment algorithms that enhance outcomes and justify premium pricing.

Digital adherence platforms and patient-centric support services should be integrated into value propositions to improve long-term compliance and capture real-world performance data. Market access teams must proactively engage payers to negotiate outcomes-based agreements, demonstrating cost offsets through reduced hospitalizations and treatment-free remission rates. Finally, emerging market expansion requires tailored pricing strategies and public-private partnerships to overcome budgetary constraints while building sustainable demand.

Rigorous Research Framework Underpinning Insights

This analysis is underpinned by a rigorous mixed-methods research framework combining comprehensive secondary research and targeted primary engagement. Secondary sources included peer-reviewed journals, clinical trial registries, regulatory filings, corporate investor presentations and patent databases. Primary research comprised in-depth interviews with key opinion leaders, hematologists, oncologists, payers and supply chain experts across major markets.

Quantitative data were triangulated through multiple sources to ensure accuracy, while qualitative insights were validated by an advisory panel of CML specialists. Market segmentation, competitive landscaping and tariff impact assessments were conducted using standardized analytical protocols. All findings underwent peer review and editorial scrutiny to uphold methodological transparency and reliability. Where data limitations existed, conservative assumptions were applied and clearly annotated to maintain integrity.

Concluding Perspectives on the Future of CML Care

In summary, the CML therapeutics market stands at a crossroads of innovation and commercial complexity. While next-generation inhibitors, combination strategies and digital health tools promise enhanced patient outcomes, evolving tariff regimes, pricing pressures and generics competition underscore the need for agile strategies. Regional disparities in access and reimbursement further complicate market entry and expansion plans, demanding nuanced approaches tailored to local contexts.

As stakeholders confront these multifaceted challenges, the ability to integrate scientific differentiation with operational resilience and value-based stakeholder engagement will determine leadership in the evolving CML landscape. The insights and recommendations presented herein offer a roadmap for navigating these dynamics and capitalizing on the high-impact opportunities that lie ahead.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Chemotherapy
      • Busulfan
      • Hydroxyurea
      • Interferon Alfa
    • Combination Agents
      • Tyrosine Kinase Inhibitor With Chemotherapy
      • Tyrosine Kinase Inhibitor With Monoclonal Antibody
    • Tyrosine Kinase Inhibitors
      • First Generation
        • Imatinib
      • Second Generation
        • Bosutinib
        • Dasatinib
        • Nilotinib
      • Third Generation
        • Ponatinib
  • Treatment Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • Mechanism Of Action
    • Chemotherapy
    • Combination Agents
    • Tyrosine Kinase Inhibition
  • Route Of Administration
    • Oral
    • Parenteral
      • Intravenous
      • Subcutaneous
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
    • Specialty Centers
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Dosage Form
    • Capsule
    • Injection
    • Powder For Injection
    • Tablet
  • Patient Age Group
    • Adult Patients
    • Geriatric Patients
    • Pediatric Patients
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Limited
  • Cipla Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Myelogenous Leukemia Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Busulfan
8.2.2. Hydroxyurea
8.2.3. Interferon Alfa
8.3. Combination Agents
8.3.1. Tyrosine Kinase Inhibitor With Chemotherapy
8.3.2. Tyrosine Kinase Inhibitor With Monoclonal Antibody
8.4. Tyrosine Kinase Inhibitors
8.4.1. First Generation
8.4.1.1. Imatinib
8.4.2. Second Generation
8.4.2.1. Bosutinib
8.4.2.2. Dasatinib
8.4.2.3. Nilotinib
8.4.3. Third Generation
8.4.3.1. Ponatinib
9. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line and Beyond
10. Chronic Myelogenous Leukemia Therapeutics Market, by Mechanism of Action
10.1. Introduction
10.2. Chemotherapy
10.3. Combination Agents
10.4. Tyrosine Kinase Inhibition
11. Chronic Myelogenous Leukemia Therapeutics Market, by Route of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
11.3.1. Intravenous
11.3.2. Subcutaneous
12. Chronic Myelogenous Leukemia Therapeutics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
12.5. Specialty Centers
13. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Chronic Myelogenous Leukemia Therapeutics Market, by Dosage Form
14.1. Introduction
14.2. Capsule
14.3. Injection
14.4. Powder For Injection
14.5. Tablet
15. Chronic Myelogenous Leukemia Therapeutics Market, by Patient Age Group
15.1. Introduction
15.2. Adult Patients
15.3. Geriatric Patients
15.4. Pediatric Patients
16. Americas Chronic Myelogenous Leukemia Therapeutics Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Chronic Myelogenous Leukemia Therapeutics Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Chronic Myelogenous Leukemia Therapeutics Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Novartis AG
19.3.2. Bristol-Myers Squibb Company
19.3.3. Pfizer Inc.
19.3.4. Takeda Pharmaceutical Company Limited
19.3.5. Sun Pharmaceutical Industries Limited
19.3.6. Teva Pharmaceutical Industries Ltd.
19.3.7. Viatris Inc.
19.3.8. Dr. Reddy’s Laboratories Ltd
19.3.9. Aurobindo Pharma Limited
19.3.10. Cipla Limited
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 93. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 96. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 98. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 100. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 101. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 102. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 104. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 114. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 117. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 122. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 189. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 191. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 192. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 193. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 195. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 198. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 199. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 204. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 205. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 206. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 207. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 210. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 230. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 231. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 232. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 234. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 235. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 236. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 237. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 238. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 240. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 243. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 245. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 246. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 249. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 251. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 255. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 258. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END U

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Myelogenous Leukemia Therapeutics market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Limited
  • Cipla Limited

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.97 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chronic Myelogenous Leukemia Therapeutics Market 2024-2028 - Product Image

Chronic Myelogenous Leukemia Therapeutics Market 2024-2028

  • Report
  • 146 Pages
  • Global
From
Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2025 - Product Image

Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
TKI for Chronic Myeloid Leukemia Market by Molecule, Mechanism, Distribution Channel, End User - Global Forecast to 2030 - Product Image

TKI for Chronic Myeloid Leukemia Market by Molecule, Mechanism, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.